Nonalcoholic steatohepatitis (NASH) is prevalent in over 70% of the obese and type II diabetes mellitus (T2DM) patients and is a leading cause of liver transplantation. Hepatic insulin resistance and inflammation mirror alterations in mitochondrial oxidative flux (beta-oxidation, tri-carboxylic acid [TCA] cycle and mitochondrial respiration), in rodent models and humans with simple steatosis. This proposal will identify new mechanisms leading to dysfunctional mitochondrial oxidative flux and development of NASH. The proposal will test the hypothesis that the severity of hepatocyte inflammation and reactive oxygen species (ROS) generation will be proportional to the rates of mitochondrial oxidative flux. Thus, attenuation of oxidative flux will provide a promising strategy to alleviate inflammation and oxidative stress in NASH and T2DM.
Aim 1 will test whether altered mitochondrial oxidative flux during the transition from simple steatosis to NASH parallel an increase in ROS production, inflammation and oxidative stress. This will be tested in a mouse model fed high fructose, high trans-fat diet which gradually transitions from simple steatosis to NASH, closely resembling human disease.
Aim 2 will investigate a novel mechanism by which chronic elevation of branched chain amino acids (BCAAs) during hepatic insulin resistance will disrupt mitochondrial oxidative flux and sustain lipogenesis.
Aim 3 will utilize a novel mouse model with a clinically relevant polymorphism in the NADH dehydrogenase subunit 2 (mt-Nd2A) allele. This unique animal model will help identify whether the upregulated antioxidant defense resulting from the beneficial effects of the mt-Nd2A allele will attenuate mitochondrial oxidative dysfunction in NASH. State-of-the-art metabolic profiling techniques in nuclear magnetic resonance and mass spectrometry will be combined with measures of ROS production and oxidative stress in liver. Direct measurements of oxidative flux through the TCA cycle relative to ATP turnover in the liver will result in a novel index of mitochondrial coupling efficiency, which will have high translational value for human studies. In conclusion, identifying key mechanisms to attenuate mitochondrial oxidative flux will provide a better paradigm to treat NASH and decrease unregulated gluconeogenesis in T2DM.

Public Health Relevance

Defects in mitochondrial oxidative metabolism are central to the etiology of fatty liver disease, a major public health problem affecting over 70% of the obese and type 2 diabetes mellitus patients. The proposal addresses novel mechanisms through which dysfunctional mitochondrial oxidative metabolism promotes inflammation, oxidative stress and onset of nonalcoholic steatohepatitis. The impact of these studies is in identifying key strategies to reduce oxidative stress and inflammation during nonalcoholic steatohepatitis, specifically by attenuating dysfunctional mitochondrial oxidative flux. These strategies will provide a better paradigm to treat steatohepatitis and type 2 diabetes mellitus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK112865-01
Application #
9285399
Study Section
Integrative Physiology of Obesity and Diabetes Study Section (IPOD)
Program Officer
Doo, Edward
Project Start
2017-04-07
Project End
2022-03-31
Budget Start
2017-04-07
Budget End
2018-03-31
Support Year
1
Fiscal Year
2017
Total Cost
$342,000
Indirect Cost
$117,000
Name
University of Maryland College Park
Department
Veterinary Sciences
Type
Schools of Earth Sciences/Natur
DUNS #
790934285
City
College Park
State
MD
Country
United States
Zip Code
20742
von Morze, Cornelius; Merritt, Matthew E (2018) Cancer in the crosshairs: targeting cancer metabolism with hyperpolarized carbon-13 MRI technology. NMR Biomed :e3937
Wu, Cheng-Yang; Satapati, Santhosh; Gui, Wenjun et al. (2018) A novel inhibitor of pyruvate dehydrogenase kinase stimulates myocardial carbohydrate oxidation in diet-induced obesity. J Biol Chem 293:9604-9613